ThromboGenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps?

With U.S. sales of its eye drug Jetrea lagging, ThromboGenics is casting about for "strategic options." The company boasts Novartis' ($NVS) Alcon unit as a marketing partner outside the U.S. but has been going it alone in the States. Is another partnership in the offing? Release | Report

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.